Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 5/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030270 | 0.84 | — | — | |
| SCHEMBL12534060 | 0.82 | ELOVL1 (0.42) | ELOVL1HCAR2EPHX2 | |
| Hydrochloric Acid SCHEMBL15941816 | 0.82 | HCAR2 (0.39) | ELOVL1HCAR2EPHX2CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL18556073 | 0.82 | HCAR2 (0.39) | ELOVL1HCAR2EPHX2CHRNB2CHRNA4 | |
| SCHEMBL23855174 | 0.77 | ELOVL1 (0.34) | ELOVL1HCAR2EPHX2 | |
| SCHEMBL21661554 | 0.77 | ELOVL1 (0.34) | ELOVL1HCAR2EPHX2 | |
| SCHEMBL23855173 | 0.77 | ELOVL1 (0.34) | ELOVL1HCAR2EPHX2 | |
| SCHEMBL12836062 | 0.76 | ELOVL1 (0.38) | ELOVL1HCAR2EPHX2 | |
| SCHEMBL26135466 | 0.74 | ELOVL1 (0.42) | ELOVL1HCAR2EPHX2 | |
| SCHEMBL26134127 | 0.74 | ELOVL1 (0.42) | ELOVL1HCAR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084982-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2019-03-21 | — | — | US | disclosed |
| EP-2742045-B1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-01-23 | — | — | EP | disclosed |
| US-20180105525-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105525-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2018-04-19 | — | — | US | disclosed |
| US-9884864-B2 | Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| US-9884864-B2 | Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| US-20170174683-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174683-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2017-06-22 | — | — | US | disclosed |
| US-9617262-B2 | Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-9617262-B2 | Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-06-19 | — | — | US | disclosed |
| WO-2013021054-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084982-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | ELOVL1 447/4885HCAR2 3604/4885BPTF 2973/4885 |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | ECI1, ALPI, PREP | ELOVL1 447/4885HCAR2 3604/4885BPTF 2973/4885 |
| US-20170174683-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | ELOVL1 447/4885HCAR2 3604/4885BPTF 2973/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ELOVL1 4025/4885HCAR2 315/4885BPTF 1423/4885 |
| US-20180105525-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | ELOVL1 447/4885HCAR2 3604/4885BPTF 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.